IP Library › Granted Patent US 9,035,061
Granted Patent B2
US 9,035,061 · App. 14/090,211 · Granted May 19, 2015

Process for preparing a biphenyl-2-ylcarbamic acid

Inventor: Pierre-Jean Colson (San Francisco, CA)
Assignee: Theravance Biopharma R&D IP, LLC
C07D401/12C07D211/46
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,035,061
App. No.
14/090,211
Granted
May 19, 2015
Kind
B2
Abstract

The invention provides a process of preparing an intermediate useful in the synthesis of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and a process of preparing a crystalline freebase of the ester.

Claims (14)

1. A process for preparing a compound of formula 8:

the process comprising the steps of:

(a) reductive amination of a compound of formula 3:

and a compound of formula 6:

in the presence of a reducing agent, to yield the compound of formula 7:

and

(b) debenzylation of the compound of formula 7 to yield the compound of formula 8; wherein step (a) and step (b) are conducted in the same reaction mixture without isolation of the intermediate from step (a); wherein steps (a) and (b) are conducted in methyltetrahydrofuran.

2. The process of claim 1 , wherein the reducing agent in step (a) is sodium triacetoxyborohydride.

3. The process of claim 1 , wherein the compound of formula 3 is prepared by the process comprising the steps of:

(i) carbobenzyloxy protection of a compound of formula 1:

where each R is independently C 1-6 alkyl or are taken together to form a dioxane or dioxolane, to yield the compound of formula 2:

and

(ii) acetal deprotection of the compound of formula 2 to yield the compound of formula 3; wherein steps (i) and (ii) are conducted in methyltetrahydrofuran, and wherein step (ii) and step (a) are conducted in the same reaction mixture without isolation of the intermediate from step (ii).

4. The process of claim 3 , wherein step (i) comprises combining the compound of formula 1 and benzyl chloroformate.

Assignments (2)
SECURITY INTEREST Recorded Sep 24, 2026
From: THERAVANCE BIOPHARMA R&D IP, LLC
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 076134/0790 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2014
From: THERAVANCE, INC.
To: THERAVANCE BIOPHARMA R&D IP, LLC
Reel/Frame 033135/0860 →
Continuity (3)
Division 13173274 · Jun 30, 2011
Provisional Application 61363725 · Jul 13, 2010
Related Publication 20140121378A1 · May 1, 2014